{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T09:31:46Z","timestamp":1780047106754,"version":"3.53.1"},"reference-count":53,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,11,30]],"date-time":"2024-11-30T00:00:00Z","timestamp":1732924800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,11,30]],"date-time":"2024-11-30T00:00:00Z","timestamp":1732924800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arch Dermatol Res"],"DOI":"10.1007\/s00403-024-03556-2","type":"journal-article","created":{"date-parts":[[2024,11,30]],"date-time":"2024-11-30T07:03:27Z","timestamp":1732950207000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Causal-inferring and molecular-docking yield new targets for malignant melanoma therapy"],"prefix":"10.1007","volume":"317","author":[{"given":"Yan","family":"Jin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xia","family":"Ding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunyuan","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,11,30]]},"reference":[{"key":"3556_CR1","doi-asserted-by":"publisher","unstructured":"Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S et al (2002) Mutations of the BRAF gene in human cancer. Nature 6892:949\u2013954. https:\/\/doi.org\/10.1038\/nature00766","DOI":"10.1038\/nature00766"},{"key":"3556_CR2","doi-asserted-by":"publisher","unstructured":"Stark M, Hayward N (2007) Genome-wide loss of Heterozygosity and Copy Number Analysis in Melanoma using high-density single-nucleotide polymorphism arrays. Cancer Res 6:2632\u20132642. https:\/\/doi.org\/10.1158\/0008-5472.CAN-06-4152","DOI":"10.1158\/0008-5472.CAN-06-4152"},{"key":"3556_CR3","doi-asserted-by":"publisher","unstructured":"Stahl JM, Sharma A, Cheung M, Zimmerman M, Cheng JQ, Bosenberg MW et al (2004) Deregulated Akt3 activity promotes development of malignant melanoma. Cancer Res 19:7002\u20137010. https:\/\/doi.org\/10.1158\/0008-5472.CAN-04-1399","DOI":"10.1158\/0008-5472.CAN-04-1399"},{"key":"3556_CR4","doi-asserted-by":"publisher","unstructured":"Lee TD, Lee OW, Brimacombe KR, Chen L, Guha R, Lusvarghi S et al (2019) A high-throughput screen of a Library of therapeutics identifies cytotoxic substrates of P-glycoprotein. Mol Pharmacol 5:629\u2013640. https:\/\/doi.org\/10.1124\/mol.119.115964","DOI":"10.1124\/mol.119.115964"},{"key":"3556_CR5","doi-asserted-by":"publisher","unstructured":"Petit V, Raymond J, Alberti C, Pouteaux M, Gallagher SJ, Nguyen MQ et al (2019) C57BL\/6 congenic mouse NRASQ61K melanoma cell lines are highly sensitive to the combination of Mek and akt inhibitors in vitro and in vivo. Pigm Cell Melanoma R 6:829\u2013841. https:\/\/doi.org\/10.1111\/pcmr.12807","DOI":"10.1111\/pcmr.12807"},{"key":"3556_CR6","doi-asserted-by":"publisher","unstructured":"Ascierto PA, Mandal\u00e0 M, Ferrucci PF, Guidoboni M, Rutkowski P, Ferraresi V et al (2023) Sequencing of Ipilimumab Plus Nivolumab and Encorafenib Plus Binimetinib for UntreatedBRAF-Mutated metastatic melanoma (SECOMBIT): a Randomized, Three-Arm, open-label phase II trial. J Clin Oncol 2:212\u2013221. https:\/\/doi.org\/10.1200\/JCO.21.02961","DOI":"10.1200\/JCO.21.02961"},{"key":"3556_CR7","doi-asserted-by":"publisher","unstructured":"Atkins MB, Lee SJ, Chmielowski B, Tarhini AA, Cohen GI, Truong T et al (2023) Combination Dabrafenib and Trametinib Versus Combination Nivolumab and Ipilimumab for patients with AdvancedBRAF-Mutant melanoma: the DREAMseq Trial\u2014ECOG-ACRIN EA6134. J Clin Oncol 2:186\u2013197. https:\/\/doi.org\/10.1200\/JCO.22.01763","DOI":"10.1200\/JCO.22.01763"},{"key":"3556_CR8","doi-asserted-by":"publisher","unstructured":"Larkin J, Ascierto PA, Dr\u00e9no B, Atkinson V, Liszkay G, Maio M et al (2014) Combined Vemurafenib and Cobimetinib inBRAF-Mutated Melanoma. New Engl J Med 20:1867\u20131876. https:\/\/doi.org\/10.1056\/NEJMoa1408868","DOI":"10.1056\/NEJMoa1408868"},{"key":"3556_CR9","unstructured":"Sauter ER, Yeo UC, von Stemm A, Zhu W, Litwin S, Tichansky DS et al (2002) Cyclin D1 is a candidate oncogene in cutaneous melanoma. Cancer Res 11:3200\u20133206. https:\/\/pubmed.ncbi.nlm.nih.gov\/12036934\/"},{"key":"3556_CR10","doi-asserted-by":"publisher","unstructured":"Lang JM, Shennan M, Njauw JCN, Luo S, Bishop JN, Harland M et al (2011) A flexible multiplex bead-based assay for detecting germline CDKN2A and CDK4 variants in Melanoma-Prone Kindreds. J Invest Dermatol 2:480\u2013486. https:\/\/doi.org\/10.1038\/jid.2010.331","DOI":"10.1038\/jid.2010.331"},{"key":"3556_CR11","doi-asserted-by":"publisher","unstructured":"Horn S, Figl A, Rachakonda PS, Fischer C, Sucker A, Gast A et al (2013) TERT promoter mutations in familial and Sporadic Melanoma. Science 6122:959\u2013961. https:\/\/doi.org\/10.1126\/science.1230062","DOI":"10.1126\/science.1230062"},{"key":"3556_CR12","doi-asserted-by":"publisher","unstructured":"Newell F, Wilmott JS, Johansson PA, Nones K, Addala V, Mukhopadhyay P et al (2020) Whole-genome sequencing of acral melanoma reveals genomic complexity and diversity. Nat Commun 1:5259. https:\/\/doi.org\/10.1038\/s41467-020-18988-3","DOI":"10.1038\/s41467-020-18988-3"},{"key":"3556_CR13","doi-asserted-by":"publisher","unstructured":"Newell F, Kong Y, Wilmott JS, Johansson PA, Ferguson PM, Cui C et al (2019) Whole-genome landscape of mucosal melanoma reveals diverse drivers and therapeutic targets. Nat Commun 1:3163. https:\/\/doi.org\/10.1038\/s41467-019-11107-x","DOI":"10.1038\/s41467-019-11107-x"},{"key":"3556_CR14","doi-asserted-by":"publisher","unstructured":"Forschner A, Hilke F, Bonzheim I, Gschwind A, Demidov G, Amaral T et al (2020) MDM2, MDM4 and EGFR Amplifications and Hyperprogression in Metastatic Acral and Mucosal Melanoma. Cancers 3:540. https:\/\/doi.org\/10.3390\/cancers12030540","DOI":"10.3390\/cancers12030540"},{"key":"3556_CR15","doi-asserted-by":"publisher","unstructured":"Shah A, Choudhary A, Jain M, Perumal S, Patel V, Parmar G et al (2024) Discovery of novel anticancer flavonoids as potential HDAC2 inhibitors: virtual screening approach based on molecular docking, DFT and molecular dynamics simulations studies. 3 Biotech 3:83. https:\/\/doi.org\/10.1007\/s13205-023-03912-5","DOI":"10.1007\/s13205-023-03912-5"},{"key":"3556_CR16","doi-asserted-by":"publisher","unstructured":"Luo L, Zhong A, Wang Q, Zheng T (2021) Structure-Based Pharmacophore Modeling, Virtual Screening, Molecular Docking, ADMET, and Molecular Dynamics (MD) Simulation of Potential Inhibitors of PD-L1 from the Library of Marine Natural Products. Mar Drugs 1. https:\/\/doi.org\/10.3390\/md20010029","DOI":"10.3390\/md20010029"},{"key":"3556_CR17","doi-asserted-by":"publisher","unstructured":"Skrivankova VW, Richmond RC, Woolf BAR, Yarmolinsky J, Davies NM, Swanson SA et al (2021) Strengthening the reporting of Observational studies in Epidemiology using mendelian randomization. JAMA 16:1614. https:\/\/doi.org\/10.1001\/jama.2021.18236","DOI":"10.1001\/jama.2021.18236"},{"key":"3556_CR18","doi-asserted-by":"publisher","unstructured":"Davis AP, Wiegers TC, Johnson RJ, Sciaky D, Wiegers J, Mattingly CJ (2023) Comparative toxicogenomics database (CTD): update 2023. Nucleic Acids Res D1:D1257\u2013D1262. https:\/\/doi.org\/10.1093\/nar\/gkac833","DOI":"10.1093\/nar\/gkac833"},{"key":"3556_CR19","doi-asserted-by":"publisher","unstructured":"Hemani G, Zheng J, Elsworth B, Wade KH, Haberland V, Baird D et al (2018) The MR-Base platform supports systematic causal inference across the human phenome. https:\/\/doi.org\/10.7554\/eLife.34408. Elife:e34408","DOI":"10.7554\/eLife.34408"},{"key":"3556_CR20","doi-asserted-by":"publisher","unstructured":"Bycroft C, Freeman C, Petkova D, Band G, Elliott LT, Sharp K et al (2018) The UK Biobank resource with deep phenotyping and genomic data. Nature 7726:203\u2013209. https:\/\/doi.org\/10.1038\/s41586-018-0579-z","DOI":"10.1038\/s41586-018-0579-z"},{"key":"3556_CR21","doi-asserted-by":"publisher","unstructured":"Bowden J, Davey Smith G, Burgess S (2015) Mendelian randomization with invalid instruments: effect estimation and bias detection through Egger regression. Int J Epidemiol 2:512\u2013525. https:\/\/doi.org\/10.1093\/ije\/dyv080","DOI":"10.1093\/ije\/dyv080"},{"key":"3556_CR22","doi-asserted-by":"publisher","unstructured":"de Bruijn I, Kundra R, Mastrogiacomo B, Tran TN, Sikina L, Mazor T et al (2023) Analysis and visualization of longitudinal genomic and clinical data from the AACR Project GENIE Biopharma Collaborative in cBioPortal. Cancer Res 23:3861\u20133867. https:\/\/doi.org\/10.1158\/0008-5472.CAN-23-0816","DOI":"10.1158\/0008-5472.CAN-23-0816"},{"key":"3556_CR23","doi-asserted-by":"publisher","unstructured":"Xiong G, Wu Z, Yi J, Fu L, Yang Z, Hsieh C et al (2021) ADMETlab 2.0: an integrated online platform for accurate and comprehensive predictions of ADMET properties. Nucleic Acids Res W1:W5\u2013W14. https:\/\/doi.org\/10.1093\/nar\/gkab255","DOI":"10.1093\/nar\/gkab255"},{"key":"3556_CR24","doi-asserted-by":"publisher","unstructured":"Lumley JA, Desai P, Wang J, Cahya S, Zhang H (2020) The derivation of a matched molecular pairs based ADME\/Tox knowledge base for compound optimization. J Chem Inf Model 10:4757\u20134771. https:\/\/doi.org\/10.1021\/acs.jcim.0c00583","DOI":"10.1021\/acs.jcim.0c00583"},{"key":"3556_CR25","doi-asserted-by":"publisher","unstructured":"Chagas CM, Moss S, Alisaraie L (2018) Drug metabolites and their effects on the development of adverse reactions: revisiting Lipinski\u2019s rule of five. Int J Pharmaceut 1\u20132:133\u2013149. https:\/\/doi.org\/10.1016\/j.ijpharm.2018.07.046","DOI":"10.1016\/j.ijpharm.2018.07.046"},{"key":"3556_CR26","doi-asserted-by":"publisher","unstructured":"Palve V, Liao Y, Remsing Rix LL, Rix U (2021) Turning liabilities into opportunities: off-target based drug repurposing in cancer. Semin Cancer Biol 209\u2013229. https:\/\/doi.org\/10.1016\/j.semcancer.2020.02.003","DOI":"10.1016\/j.semcancer.2020.02.003"},{"key":"3556_CR27","doi-asserted-by":"publisher","unstructured":"Flynn M, Heale KA, Alisaraie L (2017) Mechanism of off-target interactions and toxicity of tamoxifen and its metabolites. Chem Res Toxicol 7:1492\u20131507. https:\/\/doi.org\/10.1021\/acs.chemrestox.7b00112","DOI":"10.1021\/acs.chemrestox.7b00112"},{"key":"3556_CR28","doi-asserted-by":"publisher","unstructured":"Currie GA (1976) Serum lysozyme as a marker of host resistance. II. Patients with malignant melanoma, hypernephroma or breast carcinoma. Brit J Cancer 6:593\u2013599. https:\/\/doi.org\/10.1038\/bjc.1976.96","DOI":"10.1038\/bjc.1976.96"},{"key":"3556_CR29","doi-asserted-by":"publisher","unstructured":"Sava G (1989) Reduction of B16 melanoma metastases by oral administration of egg-white lysozyme. Cancer Chemoth Pharm 3:221\u2013222. https:\/\/doi.org\/10.1007\/BF00689588","DOI":"10.1007\/BF00689588"},{"key":"3556_CR30","doi-asserted-by":"publisher","unstructured":"Park KS, Svennerholm K, Crescitelli R, L\u00e4sser C, Gribonika I, L\u00f6tvall J (2021) Synthetic bacterial vesicles combined with tumour extracellular vesicles as cancer immunotherapy. J Extracell Vesicles 9:e12120. https:\/\/doi.org\/10.1002\/jev2.12120","DOI":"10.1002\/jev2.12120"},{"key":"3556_CR31","doi-asserted-by":"publisher","unstructured":"Strbenac D, Wang K, Wang X, Dong J, Mann GJ, Mueller S et al (2019) Melanoma Explorer: a web application to allow easy reanalysis of publicly available and clinically annotated melanoma omics data sets. Melanoma Res 3:342\u2013344. https:\/\/doi.org\/10.1097\/CMR.0000000000000533","DOI":"10.1097\/CMR.0000000000000533"},{"key":"3556_CR32","doi-asserted-by":"publisher","unstructured":"Wise M, Callen JP (2007) Azathioprine: a guide for the management of dermatology patients. Dermatol Ther 4:206\u2013215. https:\/\/doi.org\/10.1111\/j.1529-8019.2007.00134.x","DOI":"10.1111\/j.1529-8019.2007.00134.x"},{"key":"3556_CR33","doi-asserted-by":"publisher","unstructured":"Murphy L, Atherton D (2002) A retrospective evaluation of azathioprine in severe childhood atopic eczema, using thiopurine methyltransferase levels to exclude patients at high risk of myelosuppression. Brit J Dermatol 2:308\u2013315. https:\/\/doi.org\/10.1046\/j.1365-2133.2002.04922.x","DOI":"10.1046\/j.1365-2133.2002.04922.x"},{"key":"3556_CR34","doi-asserted-by":"publisher","unstructured":"Jiyad Z, Olsen CM, Burke MT, Isbel NM, Green AC (2016) Azathioprine and risk of skin Cancer in Organ Transplant recipients: systematic review and Meta-analysis. Am J Transpl 12:3490\u20133503. https:\/\/doi.org\/10.1111\/ajt.13863","DOI":"10.1111\/ajt.13863"},{"key":"3556_CR35","doi-asserted-by":"publisher","unstructured":"Lai VWY, Sinclair R (2020) Utility of azathioprine, methotrexate and cyclosporine as steroid-sparing agents in chronic Alopecia Areata: a retrospective study of continuation rates in 138 patients. J Eur Acad Dermatol 11:2606\u20132612. https:\/\/doi.org\/10.1111\/jdv.16858","DOI":"10.1111\/jdv.16858"},{"key":"3556_CR36","doi-asserted-by":"publisher","unstructured":"Messal N, Mamessier E, Sylvain A, Celis Gutierrez J, Thibult ML, Chetaille B et al (2011) Differential role for CD277 as a co-regulator of the immune signal in T and NK cells. Eur J Immunol 12:3443\u20133454. https:\/\/doi.org\/10.1002\/eji.201141404","DOI":"10.1002\/eji.201141404"},{"key":"3556_CR37","doi-asserted-by":"publisher","unstructured":"De Gassart A, Le K, Brune P, Agaugu\u00e9 S, Sims J, Goubard A et al (2021) Development of ICT01, a first-in-class, anti-BTN3A antibody for activating V\u03b39V\u03b42 T cell\u2013mediated antitumor immune response. Sci Transl Med 616:j835. https:\/\/doi.org\/10.1126\/scitranslmed.abj0835","DOI":"10.1126\/scitranslmed.abj0835"},{"key":"3556_CR38","doi-asserted-by":"publisher","unstructured":"Harly C, Guillaume Y, Nedellec S, Peign\u00e9 C, M\u00f6nkk\u00f6nen H, M\u00f6nkk\u00f6nen J et al (2012) Key implication of CD277\/butyrophilin-3 (BTN3A) in cellular stress sensing by a major human \u03b3\u03b4 T-cell subset. Blood 11:2269\u20132279. https:\/\/doi.org\/10.1182\/blood-2012-05-430470","DOI":"10.1182\/blood-2012-05-430470"},{"key":"3556_CR39","doi-asserted-by":"publisher","unstructured":"Zhou T, Sun J, Tang L, Yuan Y, Wang J, Zhang L (2023) Potential diagnostic markers and therapeutic targets for rheumatoid arthritis with comorbid depression based on bioinformatics analysis. Front Immunol 1007624. https:\/\/doi.org\/10.3389\/fimmu.2023.1007624","DOI":"10.3389\/fimmu.2023.1007624"},{"key":"3556_CR40","doi-asserted-by":"publisher","unstructured":"Lin Y, Zhou H, Li S (2022) BTN3A2 expression is connected with favorable prognosis and high infiltrating Immune in Lung Adenocarcinoma. Front Genet 848476. https:\/\/doi.org\/10.3389\/fgene.2022.848476","DOI":"10.3389\/fgene.2022.848476"},{"key":"3556_CR41","doi-asserted-by":"publisher","unstructured":"Ren H, Li S, Liu X, Li W, Hao J, Zhao N (2021) Multi-omics analysis of the expression and prognostic value of the butyrophilins in breast cancer. J Leukoc Biol 6:1181\u20131195. https:\/\/doi.org\/10.1002\/JLB.5MA0321-158RR","DOI":"10.1002\/JLB.5MA0321-158RR"},{"key":"3556_CR42","doi-asserted-by":"publisher","unstructured":"Yan MK, Orchard SG, Adler NR, Wolfe R, McLean C, Rodr\u00edguez LM et al (2022) Association between hypertension and cutaneous melanoma, and the effect of aspirin: extended follow-up of a large randomised controlled trial. Cancer Epidemiol 102173. https:\/\/doi.org\/10.1016\/j.canep.2022.102173","DOI":"10.1016\/j.canep.2022.102173"},{"key":"3556_CR43","doi-asserted-by":"publisher","unstructured":"Yan MK, Orchard SG, Adler NR, Wolfe R, McLean C, Rodriguez LM et al (2022) Effect of aspirin on Melanoma incidence in older persons: Extended follow-up of a large Randomized double-blind placebo-controlled trial. Cancer Prev Res 6:365\u2013375. https:\/\/doi.org\/10.1158\/1940-6207.CAPR-21-0244","DOI":"10.1158\/1940-6207.CAPR-21-0244"},{"key":"3556_CR44","doi-asserted-by":"publisher","unstructured":"Skriver C, Maltesen T, Dehlendorff C, Skovlund CW, Schmidt M, S\u00f8rensen HT et al (2023) Long-term aspirin use and cancer risk: a 20-year cohort study. JNCI: J Natl Cancer Inst. https:\/\/doi.org\/10.1093\/jnci\/djad231","DOI":"10.1093\/jnci\/djad231"},{"key":"3556_CR45","doi-asserted-by":"publisher","unstructured":"Fujikawa I, Ando T, Suzuki-Karasaki M, Suzuki-Karasaki M, Ochiai T, Suzuki-Karasaki Y (2020) Aspirin induces mitochondrial Ca2\u2009+\u2009remodeling in Tumor cells via ROS\u2013Depolarization\u2013voltage-gated Ca2\u2009+\u2009entry. Int J Mol Sci 13:4771. https:\/\/doi.org\/10.3390\/ijms21134771","DOI":"10.3390\/ijms21134771"},{"key":"3556_CR46","doi-asserted-by":"publisher","unstructured":"Kumar D, Rahman H, Tyagi E, Liu T, Li C, Lu R et al (2018) Aspirin suppresses PGE2 and activates AMP kinase to inhibit Melanoma Cell motility, pigmentation, and selective tumor GrowthIn vivo. Cancer Prev Res 10:629\u2013642. https:\/\/doi.org\/10.1158\/1940-6207.CAPR-18-0087","DOI":"10.1158\/1940-6207.CAPR-18-0087"},{"key":"3556_CR47","doi-asserted-by":"publisher","unstructured":"Al Saqr A, Aldawsari MF, Alrbyawi H, Poudel I, Annaji M, Mulabagal V et al (2020) Co-delivery of Hispolon and Doxorubicin Liposomes Improves Efficacy against Melanoma Cells. AAPS PharmSciTech 8:304. https:\/\/doi.org\/10.1208\/s12249-020-01846-2","DOI":"10.1208\/s12249-020-01846-2"},{"key":"3556_CR48","doi-asserted-by":"publisher","unstructured":"Dorasamy MS, AB A, Nellore K, Wong P (2019) Synergistic inhibition of melanoma xenografts by Brequinar sodium and Doxorubicin. Biomed Pharmacother 29\u201336. https:\/\/doi.org\/10.1016\/j.biopha.2018.11.010","DOI":"10.1016\/j.biopha.2018.11.010"},{"key":"3556_CR49","doi-asserted-by":"publisher","unstructured":"Fiorentzis M, Sokolenko EA, Bechrakis NE, Ting S, Schmid KW, Sak A et al (2021) Electrochemotherapy with Bleomycin enhances radiosensitivity of Uveal Melanomas: First in Vitro results in 3D cultures of primary uveal melanoma cell lines. Cancers 12:3086. https:\/\/doi.org\/10.3390\/cancers13123086","DOI":"10.3390\/cancers13123086"},{"key":"3556_CR50","doi-asserted-by":"publisher","unstructured":"Dolinsek T, Prosen L, Cemazar M, Potocnik T, Sersa G (2016) Electrochemotherapy with bleomycin is effective in BRAF mutated melanoma cells and interacts with BRAF inhibitors. Radiol Oncol 3:274\u2013279. https:\/\/doi.org\/10.1515\/raon-2016-0042","DOI":"10.1515\/raon-2016-0042"},{"key":"3556_CR51","doi-asserted-by":"publisher","unstructured":"Slater O, Kontoyianni M (2019) The compromise of virtual screening and its impact on drug discovery. Expert Opin Drug Discov 7:619\u2013637. https:\/\/doi.org\/10.1080\/17460441.2019.1604677","DOI":"10.1080\/17460441.2019.1604677"},{"key":"3556_CR52","doi-asserted-by":"publisher","unstructured":"V\u00e1squez AF, G\u00f3mez LA, Gonz\u00e1lez BA, Ria\u00f1o-Pach\u00f3n DM (2022) Identification of active compounds against Melanoma Growth by virtual screening for Non-classical Human DHFR inhibitors. Int J Mol Sci 22. https:\/\/doi.org\/10.3390\/ijms232213946","DOI":"10.3390\/ijms232213946"},{"key":"3556_CR53","doi-asserted-by":"publisher","unstructured":"Qiao X, Wu X, Chen S, Niu MM, Hua H, Zhang Y (2024) Discovery of novel and potent dual-targeting AXL\/HDAC2 inhibitors for colorectal cancer treatment via structure-based pharmacophore modelling, virtual screening, and molecular docking, molecular dynamics simulation studies, and biological evaluation. J Enzyme Inhib Med Chem 1:2295241. https:\/\/doi.org\/10.1080\/14756366.2023.2295241","DOI":"10.1080\/14756366.2023.2295241"}],"container-title":["Archives of Dermatological Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00403-024-03556-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00403-024-03556-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00403-024-03556-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,30]],"date-time":"2024-11-30T08:02:56Z","timestamp":1732953776000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00403-024-03556-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,30]]},"references-count":53,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["3556"],"URL":"https:\/\/doi.org\/10.1007\/s00403-024-03556-2","relation":{},"ISSN":["1432-069X"],"issn-type":[{"value":"1432-069X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,30]]},"assertion":[{"value":"27 July 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 October 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 November 2024","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 November 2024","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"58"}}